Table 2.
Prognostic factors for overall survival of patients with invasive micropapillary breast cancer
| Characteristic | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age | ||||||
| ≤ 50 | 1.000 | 1.000 | ||||
| 51–64 | 0.783 | 0.515–1.193 | 0.255 | 0.899 | 0.585–1.382 | 0.628 |
| ≥ 65 | 1.929 | 1.327–2.805 | 0.001 | 2.494 | 1.657–3.752 | < 0.001 |
| Race | ||||||
| White | 1.000 | – | – | – | ||
| African American | 1.001 | 0.667–1.503 | 0.995 | – | – | – |
| Other | 0.591 | 0.277–1.257 | 0.172 | – | – | – |
| Sex | ||||||
| Female | 1.000 | – | – | – | ||
| Male | 1.130 | 0.465–2.740 | 0.787 | – | – | – |
| Charlson–Deyo comorbidity score | ||||||
| 0 | 1.000 | 1.000 | ||||
| 1 | 1.871 | 1.311–2.671 | 0.001 | 1.513 | 1.049–2.183 | 0.027 |
| ≥ 2 | 3.349 | 1.898–5.910 | < 0.001 | 2.200 | 1.217–3.978 | 0.009 |
| Clinical T stage | ||||||
| 1 | 1.000 | 1.000 | ||||
| 2 | 2.052 | 1.507–2.794 | < 0.001 | 1.888 | 1.340–2.660 | < 0.001 |
| 3 | 2.345 | 1.504–3.656 | < 0.001 | 2.230 | 1.314–3.784 | 0.003 |
| 4 | 3.649 | 2.222–5.993 | < 0.001 | 2.851 | 1.602–5.073 | < 0.001 |
| Clinical N stage | ||||||
| 0 | 1.000 | 1.000 | ||||
| 1 | 1.546 | 1.122–2.130 | 0.008 | 1.194 | 0.771–1.850 | 0.426 |
| 2 | 3.832 | 2.390–6.147 | < 0.001 | 2.009 | 1.099–3.676 | 0.024 |
| 3 | 1.825 | 0.852–3.908 | 0.122 | 0.925 | 0.292–2.184 | 0.859 |
| Surgery | ||||||
| Lumpectomy | 1.000 | 1.000 | ||||
| Mastectomy | 1.373 | 1.040–1.812 | 0.025 | 1.027 | 0.751–1.404 | 0.869 |
| Radiotherapy | ||||||
| Yes | 1.000 | 1.000 | ||||
| No | 1.755 | 1.336–2.307 | < 0.001 | 2.344 | 1.711–3.210 | < 0.001 |
| Histologic grade | ||||||
| Well differentiated | 1.000 | – | – | – | ||
| Moderately differentiated | 0.981 | 0.558–1.723 | 0.946 | – | – | – |
| Poorly differentiated/undifferentiated | 1.457 | 0.831–2.552 | 0.189 | – | – | – |
| Not reported | 0.721 | 0.291–1.788 | 0.481 | – | – | – |
| ER status | ||||||
| Positive | 1.000 | 1.000 | ||||
| Negative | 2.245 | 1.629–3.113 | < 0.001 | 2.804 | 1.827–4.305 | < 0.001 |
| Unknown | 0.704 | 0.260–1.906 | 0.490 | 0.585 | 0.211–1.626 | 0.304 |
| PR status | ||||||
| Positive | 1.000 | 1.000 | ||||
| Negative | 1.6501 | 1.223–2.227 | 0.001 | 1.586 | 1.166–2.156 | 0.003 |
| Unknown | 0.731 | 0.298–1.788 | 0.492 | 0.825 | 0.335–2.045 | 0.677 |
| HER2 status | ||||||
| Positive | 1.000 | – | – | – | ||
| Negative | 1.021 | 0.604–1.728 | 0.937 | – | – | – |
| Unknown | 0.857 | 0.503–1.460 | 0.570 | – | – | – |
| Chemotherapy | ||||||
| Yes | 1.000 | – | – | – | ||
| No | 0.914 | 0.679–1.230 | 0.552 | – | – | – |
| Not reported | 1.314 | 0.874–1.977 | 0.189 | – | – | – |
| Hormonal therapy | ||||||
| Yes | 1.000 | 1.000 | ||||
| No | 1.526 | 1.134–2.054 | 0.005 | 0.789 | 0.538–1.158 | 0.227 |
| Not reported | 1.296 | 0.745–0.254 | 0.358 | 1.013 | 0.567–1.810 | 0.965 |
| Lymph nodes involved | ||||||
| 0 | 1.000 | 1.000 | ||||
| 1–3 | 0.971 | 0.656–1.438 | 0.883 | 1.087 | 0.700–1.687 | 0.711 |
| 4 or more | 2.438 | 1.750–3.398 | < 0.001 | 2.292 | 1.413–3.719 | 0.001 |
| Unknown | 1.823 | 1.174–0.828 | 0.007 | 1.507 | 0.962–2.361 | 0.073 |
OS overall survival, HR hazard ratio, CI confidence interval, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2